52-Week Highs and Lows, April 9, 2026

24 new highs, 1 new low.

Highs

JAZZ .. $200.24 .. Jazz Pharmaceuticals. Large cap specialty pharma, diversified across sleep, oncology, and neuroscience. Xywav/Xyrem franchise continues to anchor the business. 52W low was around $89. This name has been on a relentless grind higher.

RLMD .. $7.65 .. Relmada Therapeutics. Pivoted to NDV-01 for bladder cancer after the REL-1017 depression program was terminated. 12-month Phase 2 data showed 76% complete response rate, 95% at any time. Oversubscribed $160M PIPE at $4.75 in March, cash runway through 2029. Phase 3 RESCUE program starting mid-2026. 52W low was around $2.80, up roughly 170% from there.

RLAY .. $15.00 .. Relay Therapeutics. Precision medicine biotech using computational approach to drug discovery. Pipeline focused on oncology targets. Miami T3 name. 52W low was around $4.50, more than tripled from the bottom.

ALLO .. $2.91 .. Allogene Therapeutics. Allogeneic CAR-T cell therapy platform. Core M&A vertical, big pharma has been aggressively consolidating in cell therapy. 52W low was near $1.15. Up roughly 150% from the trough.

ANAB .. $69.13 .. AnaptysBio. Immunology-focused biotech with multiple programs in inflammation and autoimmune disease. Roivant partnership adds optionality. 52W low was around $18.

XBI .. $133.27 .. SPDR S&P Biotech ETF. The sector benchmark hitting new highs tells you the tape is healthy. Broad-based bio rally. 52W low was around $75, up nearly 80% from there.

LXRX .. $1.84 .. Lexicon Pharmaceuticals. Commercial-stage biotech with sotagliflozin (INPEFA) for heart failure. Miami T2 name. 52W low was around $0.60, tripled from the bottom.

MPLT .. $29.55 .. Monopar Therapeutics. Clinical-stage biotech, radioprotective agent MNPR-101 is the lead program. Miami T2 name. 52W low was around $2.50. Massive move, nearly 12x from the lows.

ETON .. $27.19 .. Eton Pharmaceuticals. Specialty pharma focused on rare disease and hospital products. Growing revenue base with multiple approved products. Miami T3 name. 52W low was around $3.50, up roughly 675%.

NFBK .. $14.11 .. Northbrook Bank & Trust (Northeast Bank). Regional bank name. Community banking in the northeast. 52W low around $9.50. Banking sector strength continues.

CASY .. $774.23 .. Casey's General Stores. Convenience store and fuel retailer, Midwest footprint. Not a bio name, not a bank, but a steady compounder. 52W low around $340.

ELVN .. $46.23 .. Enliven Therapeutics. Precision oncology, lead asset ELVN-001 targeting CML. Phase 3 ENABLE-2 pivotal trial planned H2 2026. $463M cash, runway into 2029. Merck acquisition news validated the precision oncology space in March. Mizuho raised PT to $45 from $41. 52W low was around $13.30, up roughly 250%.

NECB .. $25.65 .. NorthEast Community Bancorp. Another community bank hitting highs. 52W low around $16. Banking scan note, local/regional target profile.

APGE .. $87.00 .. Apogee Therapeutics. Immunology/inflammation focused, developing antibody-based therapies. Pipeline in atopic dermatitis and COPD. 52W low around $23. Nearly 4x from the bottom.

IRD .. $5.57 .. iRadimed. Medical devices, MRI-compatible IV infusion pumps and patient monitoring. Miami T1 name. 52W low was around $2.50. More than doubled from there.

TRDA .. $14.36 .. Entrada Therapeutics. Intracellular biologics platform, endosomal escape technology for delivering therapeutics inside cells. Oppenheimer raised PT to $23 from $21 with Outperform. Cantor Fitzgerald initiated Overweight. Guggenheim has a Strong Buy. 52W low was around $5.50, up roughly 160%.

OVID .. $3.10 .. Ovid Therapeutics. CNS-focused biotech, programs in rare neurological conditions. Miami T3 name. 52W low was around $0.60, up roughly 400% from there.

CARE .. $24.86 .. Carter Bankshares. Regional bank in Virginia and West Virginia. Community banking, solid footprint. 52W low around $15. Banks keep grinding.

SYRE .. $54.39 .. Spyre Therapeutics. GI-focused biotech, developing next-gen antibodies for IBD. Miami T1 name. 52W low was around $15. Up roughly 260% from the bottom.

SRRK .. $51.62 .. Scholar Rock Holding. Muscle biology focused, lead program apitegromab targeting SMA. Miami T2 name. 52W low was around $10. Up roughly 400% from there.

C .. $125.48 .. Citigroup. Major money center bank hitting fresh highs. Banking scan note, Citi is a frequent acquirer and M&A advisory presence. 52W low around $55.

CLYM .. $8.16 .. Calyme Therapeutics. GI and inflammation focused biotech, oral small molecule programs. Miami T1 name. 52W low around $2.50. More than tripled.

CGEN .. $2.49 .. Compugen. Computational biology-driven immuno-oncology biotech. Pipeline includes checkpoint targets. 52W low around $0.90, nearly tripled.

FBRX .. $35.80 .. Forte Biosciences. Dermatology-focused biotech. 52W low was around $1.50. This is a massive runner, up roughly 23x from the bottom.

Lows

AGMB .. $9.00 .. AgomAb Therapeutics. New 52-week low. Clinical-stage biotech focused on fibrosis and organ restoration, agonist monoclonal antibody platform. Recent IPO, Leerink initiated at Outperform with $36 PT, JPMorgan Overweight $32, Morgan Stanley Overweight $28. Hit $17.45 high in March and has been sliding since. Worth watching at these levels given the analyst backing and Leerink involvement.

Summary: 24 new highs versus just 1 new low. Heavy bio day with 18 of the 24 highs being biotech or specialty pharma names. Three bank names on the list (NFBK, NECB, CARE) plus Citigroup, so the banking bid remains alive. Eight Miami Health Week names represented across the tiers (RLAY T3, LXRX T2, MPLT T2, ETON T3, IRD T1, OVID T3, SYRE T1, SRRK T2, CLYM T1). XBI hitting new highs at $133 confirms this is a broad sector move, not just single-name noise. The lone new low, AGMB, is a recent IPO pulling back hard from its March highs with heavy analyst support underneath, Leerink-covered. FBRX is the standout mover at 23x off its 52W low. Breadth is strong, tape is healthy.